肾细胞癌3p21杂合子丢失的分子病理研究

A pathological study on the loss of heterozygosity of 3p21 in renal cell carcinoma

应用聚合酶链反应－限制性片段长度多态性分析技术检测３１例非乳头状肾细胞癌３ｐ２１杂合子丢失。结果显示：肾细胞癌中３ｐ２１杂合子率为３８．７％，杂合子丢失率为６６．７％。杂合子丢失阳性患者的５年存活率为２５．０％，而杂合子丢失阴性和纯合子未丢失患者的５年存活率为６５．２％，二者比较，差异有显著性（Ｐ＜０．０５）。提示３ｐ２１杂合子丢失可能与非乳头状肾细胞癌的演化及预后有关。

Polymerase chain reaction-restriction fragment lenghth polymorphisms(PCR-RELP)analytic technique to detect the loss of heterozygosity(LOH)of 3p21 was carried out in 31 cases of nonpapillary renal cell carcinoma(RCC).The rate of heterozygosity was 38.7% and the rate of LOH 66.7% in RCC. The 5-year survival rate was 25. 0% in LOH positive cases while it was 65.2% in the LOH negative cases and in those with no loss of homozygosity.The difference between the 2 groups was stastically significant(P<0.05).It was suggested that LOH of 3p21 might be related to the evolution and prognosis in nonpapillary RCC.